Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation.

MAbs · 2019 · PMC6380423 · PMID 30569825

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The effect mediated by the biAb showed a trend of being more potent than the bivalent anti-CD19 mAb (88% vs 66% reduction, respectively, of BCR-mediated B-cell proliferation).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.